GlassScriptPhysician profile
Yusuf Deshmukh
NPI 1972585883
$16,230.79
in general payments reported to CMS, 2019-2025
84 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $1,378 · 2021: $2,668 · 2022: $2,728 · 2023: $2,374 · 2024: $2,327 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,125 · Education: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,124.97 |
| Education | $533.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,637.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,493.04 | 2019-2025 | Tagrisso, Enhertu, Atacand |
| Janssen Biotech, INC. | $876.52 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Pfizer INC. | $864.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $724.08 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $673.52 | 2019-2025 | |
| Seagen INC. | $670.18 | 2020-2023 | Padcev, Adcetris |
| Daiichi Sankyo INC. | $660.21 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $504.97 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $433.08 | 2020-2024 | Lumakras, Nplate, Vectibix |
| Celgene Corporation | $424.79 | 2019-2025 | Reblozyl, Opdivo |
| Incyte Corporation | $420.42 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Rigel Pharmaceuticals, INC. | $412.04 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $374.87 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $362.03 | 2021-2025 | Venclexta |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuf Deshmukh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.